Increasing evidence suggests that up-regulation of PDCD4 in breast cancer may improve the sensitivity to systemic therapeutic drugs, especially for patients given neoadjuvant chemotherapy (preoperative chemotherapy where radical surgery is feasible), and thereby reduce tumor size, increase the chance of breast-conserving surgery and prolong lifespan. Here, PDCD4 is linked to neoplasm.